Piramal Pharma invests Rs 102 crore in Yapan Bio for significant minority stake

Biologics capabilities can be synergistic with the company's anti-body drug conjugation capabilities; specifically, for customers who prefer the speed and simplicity benefits of an integrated program that involves development, manufacturing, conjugation, and fill finish. PPS currently offers integrated payload, conjugation, fill finish services, and the addition of anti-body capabilities enhances that offering.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3FkhorC
via IFTTT